- Conditions
- Ebola Virus Disease, Marburg Virus Disease
- Interventions
- cAd3-Marburg, cAd3-EBO-S
- Biological
- Lead sponsor
- Albert B. Sabin Vaccine Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1033–1056
of 1,235
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2
- Interventions
- No intervention
- Other
- Lead sponsor
- American Dental Association
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,196 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4, SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- Abatacept, Placebo
- Biological · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Hialeah, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Multiple Sclerosis, Healthy
- Interventions
- Blood draw
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- COVID-19 Prevention
- Interventions
- Q-Griffithsin 3.0, Q-Griffithsin 6.0
- Drug
- Lead sponsor
- Kenneth Palmer
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- COVID-19, SARS-CoV-2 Infection, Corona Virus Infection
- Interventions
- ARCT-165, ARCT-154, ARCT-021
- Biological
- Lead sponsor
- Arcturus Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Wichita, Kansas • Kansas City, Missouri
- Conditions
- Cognitive Impairment, Long COVID
- Interventions
- Digital cognitive behavioral intervention-RxWell, Amphetamine-Dextroamphetamine
- Behavioral · Drug
- Lead sponsor
- Eva Szigethy
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- COVID-19
- Interventions
- casirivimab+imdevimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Minute to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Stony Brook, New York • Memphis, Tennessee
- Conditions
- COVID, Sars-CoV2, COVID-19, Acute Respiratory Distress Syndrome
- Interventions
- Defibrotide
- Drug
- Lead sponsor
- Gregory Yanik
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Critically Illness, Sedation, Invasive Mechanical Ventilation, Acute Respiratory Distress Syndrome
- Interventions
- Intravenous sedation, Inhaled sedation
- Drug
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- COVID-19, SARS CoV 2 Infection
- Interventions
- LumiraDX, RightSign, Case Control
- Diagnostic Test
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Post-Acute COVID-19, Post COVID-19 Condition, Post Viral Fatigue, Dyspnea
- Interventions
- Computed Tomography of the Chest
- Diagnostic Test
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Covid19
- Interventions
- OL-1, standard dose, OL-1, high dose, Placebo
- Dietary Supplement
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Covid19
- Interventions
- CAP-1002, Placebo
- Biological
- Lead sponsor
- Capricor Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Sacramento, California • Detroit, Michigan + 1 more
- Conditions
- Burnout, Stress, Emotional
- Interventions
- Positive feedback
- Behavioral
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- COVID 19
- Interventions
- Saline Nasal Irrigation, Saline with Baby Shampoo Nasal Irrigation
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- SARS-COV2 Virus
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Year to 90 Years
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Pittsburgh, Pennsylvania
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273 Variant-containing Formulation
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 1,144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Baton Rouge, Louisiana + 3 more
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, COVID-19
- Interventions
- LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B
- Diagnostic Test
- Lead sponsor
- LumiraDx UK Limited
- Industry
- Eligibility
- Not listed
- Enrollment
- 716 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 10
- States / cities
- Garden Grove, California • Lomita, California • DeLand, Florida + 6 more
- Conditions
- Vaccine Refusal, Covid19
- Interventions
- COVID-19 Individual Awareness and Education., COVID-19 Community Outreach & Health Promotion., COVID-19 Individual Health Education & Linkages to Medical and Supportive Services., Pop-up community vaccination sites
- Behavioral · Biological
- Lead sponsor
- Britt Skaathun
- Other
- Eligibility
- 16 Years to 99 Years
- Enrollment
- 1,051 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Chula Vista, California • San Diego, California • San Ysidro, California
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b5 Bivalent (WT/OMI BA.2), BNT162b2 Bivalent (WT/OMI BA.1), BNT162b2 Bivalent (WT/OMI BA.4/BA.5), BNT162b5 Bivalent (Original/OMI BA.4/BA.5), BNT162b6 Bivalent (Original/OMI BA.4/BA.5), BNT162b7 Bivalent (Original/OMI BA.4/BA.5), BNT162b7 Monovalent (OMI BA.4/BA.5)
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,453 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 31
- States / cities
- Anaheim, California • San Diego, California • Valley Village, California + 26 more
- Conditions
- COVID-19, SARS-COV-2 Infection
- Interventions
- BNT162b2 (2025/2026 formulation)
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 27
- States / cities
- Palo Alto, California • San Diego, California • Homestead, Florida + 21 more
- Conditions
- Covid19
- Interventions
- Weight-based dexamethasone dose
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York